CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
CytoDyn presented data from an ongoing Phase 2 study at AACR 2026, showing that leronlimab combined with TAS-102 and bevacizumab achieved a median 70% reduction in circulating tumor DNA by week 2. The regimen was well tolerated with no dose-limiting toxicities observed, and CCR5 expression was detected in 100% of pre-screened patients, validating the target.
Key figures
- Drug Name
- leronlimab
- Phase Of Trial
- Phase 2
- Ct DNA decline
- 70%
- Dose escalation mg
- 700
- CCR5 expression rate
- 100%
- Patients evaluable ct DNA
- 19
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.